Sansure and Singlera Officially Entering the Field of Screening and Early Detection of Cancer Through Their Newly Established Joint Venture
Jiangsu Yang Shengyuan Biotech Co. Ltd., a joint venture, was jointly established by Sansure Biotech and Singlera recently, in which Sansure Biotech holds 40% and Singlera holds 60%.
Based on the advantages of its two shareholders, the joint venture will work on livelihood projects in accordance with national policies. In order to contribute to the improvement of the national health level, it will also conduct extensive cooperation in various fields such as ctDNA extraction, automation equipment for methylation processing, cancer species, cancer application segmentation and international market development.
According to the data, 4.57 million new cancer cases and around 3 million deaths were reported in China in 2020. Early screening of cancer is one of the major means of cancer prevention and control, which can effectively reduce the burden of medical expenditure and improve survival rate of patients. At present, the field of screening and early detection of cancer is developing rapidly with a broad prospect.
With developed product lines, Singlera can provide full-cycle products and services such as risk assessment, early screening and early diagnosis, medication guidance and recurrence monitoring of high-risk cancers, covering lung cancer, colorectal cancer, liver cancer, gastric cancer and many other high-risk cancers. Among them, the research results of ColonAiQ®, an early screening product for blood polygenic methylation detection of colorectal cancer originally produced in China, were published by the top international journals in the field of gastrointestinal diseases; PanSeer®, an independently developed methylation pan-cancer screening technology for circulating tumor DNA (ctDNA), was the first in the world to realize the verification of pan-cancer early screening technology in large natural population queues.
Sansure Biotech has built comprehensive product lines covering different groups of people throughout the whole life cycle, developed a series of more than 1,000 products with performance surpassing the advanced level at home and abroad, and further expanded into the field of early screening of cancers and individualized drug use of tumors, and developed molecular diagnosis solutions for early screening of cancers through independent research and development or cooperation in the introduction of early screening and diagnosis products of methylation, liquid biopsy and multi-omics, which is used for full-cycle products and services such as risk assessment, early screening and early diagnosis, medication guidance and recurrence monitoring of high-risk cancers Among them, the early screening kit for liver cancer based on DNA methylation detection independently developed by Sansure Biotech has entered the clinical research stage, and the research and development of early screening products for gastric cancer and intestinal cancer are expected to be completed this year.
In terms of product lines, the joint venture established by Sansure Biotech and Singlera will combine the R&D capabilities of both parties, enrich the product line of screening and early detection of cancer and improve product competitiveness; in terms of product international registration, the company will continue to promote the market share with the help of the Biotech international team; and in terms of market channels, it will speed up the development of products in the international market, strengthen the deep cultivation and layout of the international market, and lay a foundation for further development of the international market in the future with the mature channel management mode of Sansure Biotech.
